HI
BMRN icon

HBK Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

HBK Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16,600
Closed -$1.12M – 667
2019
Q3 		$1.12M Sell
16,600
-13,600
-45% -$1.05M 0.01% 486
2019
Q2 		$2.59M Buy
+30,200
New +$2.58M 0.02% 327

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

HBK Investments's BMRN Position: Q4 2019 in Review

HBK Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 19,000 shares — an estimated $1.28M sold.

HBK Investments first reported a position in BMRN in Q2 2013 and held it in 4 quarters. The position peaked at $3.14M in Q2 2019. 468 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

  • HBK Investments reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • HBK Investments sold 19,000 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $1.28M.
  • HBK Investments first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • HBK Investments's BioMarin Pharmaceuticals position peaked at $3.14M in Q2 2019.
  • 468 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on HBK Investments's 13F filing for Q4 2019, filed 14 Feb 2020.